Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team

Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and
                         Joins Shire Leadership Team

  PR Newswire

  LA JOLLA, California, November 15, 2012

LA JOLLA, California, November 15, 2012 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), announces that Jeff Jonas M.D. has been
appointed President of Shire's Regenerative Medicine (RM) business, effective
November 15, 2012. Jeff will report to Shire Chief Executive, Angus Russell,
and will join the Shire Leadership Team. 

After a varied career in research & development, commercial and
entrepreneurial business roles, Jeff joined Shire in July 2008 as leader of
the Specialty Pharmaceuticals (SP) Research & Development (R&D) team. 

Jeff has been closely involved with the RM business since Shire acquired it as
Advanced BioHealing in June 2011. In addition to his role as head of the SP
R&D team, Jeff has been leading the RM R&D team and has been a member of the
RM leadership team. Jeff will lead the newly established RM team to take the
business to its next stage of growth.

Jeff's role as head of the SP R&D team will be filled by Arnaud Partiot M.D.
Arnaud is a qualified psychiatrist and has been a senior member of the Shire
SP team in various clinical research & development, medical affairs and
commercial roles since joining Shire in 2004.

Kevin Rakin, who led Advanced BioHealing Inc. since 2007 and during its
integration into Shire, is stepping down from his position as Regenerative
Medicine President and from the Shire Leadership Team to pursue new career
interests. Kevin will be available to provide transitional support through 28
December 2012. 

Says Shire Chief Executive, Angus Russell:

"We are pleased with the progress we are making in transforming our
Regenerative Medicine business. Jeff's insight and experience will enable us
to build on this as we shape this business for future growth. We have great
ambition for this business and we're committed to seeing those ambitions

"I'd like to recognise Kevin Rakin as a leader of this business during its
integration into Shire; and we wish him well in his new endeavours. "

Says Jeff Jonas:

"Shire's Regenerative Medicine business has so much potential; it serves a
growing patient population with unmet needs and we have an excellent,
differentiated product in DERMAGRAFT, already commercialised for diabetic foot
ulcers. We're exploring other possible indications for DERMAGRAFT and we
believe we can expand its use into new geographies. The science and
technology in regenerative medicine is developing well and we see many
opportunities to acquire other exciting assets to build a robust and
attractive pipeline. Leading this business to greater heights is a very
exciting opportunity for me."

Further background on Jeff Jonas

Before joining Shire in 2008, he served as Executive Vice President at Isis
Pharmaceuticals in charge of clinical and pre-clinical development, regulatory
affairs, quality assurance and compliance, and had broad responsibility for
the product pipeline.

Prior to this, Jeff was Chief Medical Officer and Executive Vice President at
Forest Laboratories, Inc.

He began his career at Upjohn Laboratories where he advanced to the position
of Chief Medical Officer.

Jeff has also been a successful entrepreneur. He founded and led AVAX
Technologies, a leader in autologous cell therapy and individualized therapy.
Dr. Jonas led AVAX through several successful financings, including an initial
public offering in 1997.

In 2001, he co-founded SCEPTOR Industries, a biotechnology company involved in
biodefense surveillance.

Jeff has published more than 70 scientific papers and chapters and has
received a number of awards.

Jeff received his M.D. from Harvard Medical School and completed a residency
in psychiatry at Harvard. Shortly thereafter, he was appointed Chief Resident
in psychopharmacology at McLean Hospital, Harvard Medical School.

Notes to editors


Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide
healthcare in the areas of:

  *Behavioral Health and Gastro Intestinal conditions
  *Rare Diseases
  *Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for
patients, physicians, policymakers, payors and our shareholders.

For further information on Shire, please visit the Company's website:
http://www.shire.com .


Statements included herein that are not historical facts are forward-looking
statements. Such forward-looking statements involve a number of risks and
uncertainties and are subject to change at any time. In the event such risks
or uncertainties materialize, the Company's results could be materially
adversely affected. The risks and uncertainties include, but are not limited
to, risks associated with: the inherent uncertainty of research, development,
approval, reimbursement, manufacturing and commercialization of the Company's
Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine
products, as well as the ability to secure new products for commercialization
and/or development; government regulation of the Company's products; the
Company's ability to manufacture its products in sufficient quantities to meet
demand; the impact of competitive therapies on the Company's products; the
Company's ability to register, maintain and enforce patents and other
intellectual property rights relating to its products; the Company's ability
to obtain and maintain government and other third-party reimbursement for its
products; and other risks and uncertainties detailed from time to time in the
Company's filings with the Securities and Exchange Commission.

For further information please contact: Investor Relations   Eric Rojas  
erojas@shire.com   +1-781-482-0999Sarah Elton-Farr   seltonfarr@shire.com
  +44-1256-894157 Media   Jessica Mann (Corporate)   jmann@shire.com 
 +44-1256-894-280Lindsey Hart (Regenerative Medicine)   lhart@shire.com
Press spacebar to pause and continue. Press esc to stop.